Much anticipated news has just been announced!
ViaCyte has filed documentation with the U.S. Food and Drug Administration (FDA) for its innovative encapsulated cell replacement therapy according to a company announcement. This important milestone is a key step on the path to conducting the first clinical study of this potentially transformative therapy for people with type 1 diabetes (T1D).
Thanks to the support of donors like you, JDRF provided funding to support ViaCyte’s clinical studies of this exciting experimental therapy. The recent filing brings us one step closer to the start of these studies. All documentation is now under review by the FDA, who will determine soon whether ViaCyte has a green light to begin its first study.
JDRF has made its encapsulation research program a priority because of its potential to transform the way individuals with T1D manage their disease.
JDRF donors helped make possible this important step towards our goal of creating a world without T1D.